+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Preimplantation Genetic Testing (PGT) (PGS/PGD) Market Size, Share & Trends Analysis Report By PGD/PGS, By Type (Embryo Testing, Aneuploidy Screening), By Application, And Segment Forecasts, 2019 - 2024

  • ID: 4764578
  • Report
  • January 2017
  • 170 pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • Bioarray S.L.
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genea Limited
  • IGENOMIX
  • Illumina, Inc.
  • MORE
The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.

High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.

Further key findings from the report suggest:
  • Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018
  • Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in near future
  • Advancements in detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018
  • Expanding utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is expected to fuel the growth of X-linked diseases segment
  • Implementation of PGT in embryo HLA typing for stem cell therapy is expected to impose segment growth. This is further attributed to the advantages pertaining to PGS testing for identification of HLA compatible embryos during stem cell therapy
  • Europe accounts for largest revenue share in 2018 owing to increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures
  • Asia Pacific market is observed to reveal the fastest CAGR due to the rise in medical tourism and the continuous development of IVF and PGD clinics in Asian countries
  • Key players that have commercialized PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others
  • Key participants are actively involved in expansion of the distribution network for their products as well as R&D activities for the development of novel PGT services. In October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bioarray S.L.
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genea Limited
  • IGENOMIX
  • Illumina, Inc.
  • MORE
Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 Internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing

Chapter 2 Executive Summary
2.1 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market Outlook, 2014 - 2024
2.2 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: Segment Outlook, 2014 - 2024
2.3 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: Competitive Insights

Chapter 3 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market Variables, Trends& Scope
3.1 Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping, 2018
3.3 Product Pipeline Analysis, by Stage
3.4 Cost Structure Analysis
3.5 User Perspective Analysis
3.5.1. Consumer behavior analysis
3.5.2. Market influencer analysis
3.6 Procedure Cost Analysis/Breakdown
3.7 End-use analysis
3.8 Regulatory Framework
3.8.1. Reimbursement framework
3.8.2. Standards & compliances
3.9 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market - Market Dynamics
3.9.1 Market driver analysis
3.9.1.1 Rising incidences of genetic diseases
3.9.1.2 Demand for healthy and successful embryo implantation
3.9.1.3 Increase in rate of infertility
3.9.2 Market Restraint Analysis
3.9.2.1 Ethical and legal constraints
3.9.3 Market challenges analysis
3.9.3.1 Challenges related to invasive embryo biopsy during PGD
3.10 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market Analysis Tools
3.10.1 Industry Analysis - Porter’s
3.10.1.1 Supplier power: Moderate bargaining power of suppliers owing to low switiching cost
3.10.1.2 Buyer power: Increase in cost containment results in moderate bargaing power of buyer
3.10.1.3 Substitution threat: Low threat of substitution due to stringent approval procedure
3.10.1.4 Threat from new entrant: Threat of new entrant is low as high capital is required for PGT set up
3.10.1.5 Competitive rivalry: There is high competitive rivalry owing to high demand of IVF technology
3.10.2 PESTEL analysis
3.10.2.1 Political landscape
3.10.2.2 Environmental landscape
3.10.2.3 Social landscape
3.10.2.4 Technology landscape
3.10.2.5 Legal landscape
3.10.3 Major deals & strategic alliances analysis
3.10.3.1 Joint ventures
3.10.3.2 Mergers & acquisitions
3.10.3.3 Licensing & partnership
3.10.3.4 Technology collaborations
3.10.3.5 Strategic divestments
3.10.4 Market entry strategies
3.10.5 Case studies
3.11 Global preimplantation genetic testing (PGT)(PGS/PGD) company market share, 2018
3.12 U.S. preimplantation genetic testing (PGT)(PGS/PGD)company market share, 2018
3.13 Platform comparison
3.13.1 Share break-up analysis in terms of commercial test kits (Veriseq, Reproseq) v/s in-house developed PGD/PGS testing
3.13.1.1 Veriseq
3.13.1.2 Reproseq
3.13.1.3 Other Kits

Chapter 4 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.3.1 Distribution network
4.3.2 Key customers
4.3.3 Key company market share analysis, 2018
4.4 Public Companies
4.4.1 Company market position analysis
4.4.2 Company market share by region
4.4.3 Competitive dashboard analysis
4.4.4 Market differentiators
4.4.5 Synergy analysis: Major deals & strategic alliances
4.5 Private Companies
4.5.1 List of key emerging companies
4.5.2 Funding outlook
4.5.3 Regional network map
4.5.4 Company market position analysis

Chapter 5 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: PGD/PGS Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 PGD/PGS Market Share Analysis, 2018 & 2024
5.3 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market Share by PGD/PGS, 2014 to 2024
5.4 Global Preimplantation Genetic Testing (PGT) (PGS/PGD) Market by PGD/PGS, 2014 to 2024
5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2024 for the following,
5.5.1 PGD
5.5.1.1 Global PGD market, 2014 - 2024 (USD Million)
5.5.1.2 Pricing Analysis of PGD tests
5.5.1.3 PGD lab revenue, 2014 - 2024, by lab size, (USD Million)
5.5.1.3.1 High
5.5.1.3.1.1 High capacity PGD labs market, 2014 - 2024, by region
5.5.1.3.2 Medium
5.5.1.3.2.1 Medium capacity PGD labs market, 2014 - 2024, by region
5.5.1.3.3 Low
5.5.1.3.3.1 Low capacity PGD labs market, 2014 - 2024, by region
5.5.1.4 Number of labs offering PGD in different regions
5.5.1.5 Number of IVF cycles for PGD in different regions
5.5.1.6 PGD Technology Analysis
5.5.1.6.1 aCGH
5.5.1.6.1.1 aCGH capacity PGD labs market, 2014 - 2024, by region
5.5.1.6.2 NGS
5.5.1.6.2.1 NGS capacity PGD labs market, 2014 - 2024, by region
5.5.1.6.3 Other technologies
5.5.1.3.6.1 Other technologies capacity PGD labs market, 2014 - 2024, by region
5.5.2 PGS
5.5.2.1 Global PGS market, 2014 - 2024 (USD Million)
5.5.2.2 Pricing Analysis of PGS tests
5.5.2.3 PGS lab revenue, 2014 - 2024, by lab size, (USD Million)
5.5.2.3.1 High
5.5.2.3.1.1 High capacity PGS labs market, 2014 - 2024, by region
5.5.2.3.2 Medium
5.5.2.3.2.1 Medium capacity PGS labs market, 2014 - 2024, by region
5.5.2.3.3 Low
5.5.2.3.3.1 Low capacity PGS labs market, 2014 - 2024, by region
5.5.2.4 Number of labs offering PGS in different regions
5.5.2.5 Number of IVF cycles for PGS in different regions
5.5.2.6 PGD Technology Analysis
5.5.2.6.1 aCGH
5.5.2.6.1.1 PGS - aCGH market, 2014 - 2024, by region
5.5.2.6.2 NGS
5.5.2.6.2.1 PGS - NGS market, 2014 - 2024, by region
5.5.2.6.3 Other technologies
5.5.2.3.6.1 PGS - Others technologies market, 2014 - 2024, by region
5.6 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market, by Application, 2014 to 2024

Chapter 6 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: Types Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Type Market Share Analysis, 2018 & 2024
6.3 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: End-use Movement Analysis, 2018 & 2024
6.4. Global Preimplantation Genetic Testing (PGT) (PGS/PGD) Market, by Type, 2014 to 2024
6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2024 for the following,
6.5.1 X-linked diseases
6.5.1.1 Global X-linked diseases market, 2014 - 2024 (USD Million)
6.5.2 Embryo testing
6.5.2.1 Global embryo testing market, 2014 - 2024 (USD Million)
6.5.2.2 Fresh embryo (own eggs)
6.5.2.2.1 Global fresh embryo (own eggs) testing market, 2014 - 2024 (USD Million)
6.5.2.3 Frozen embryo (own eggs)
6.5.2.3.1 Global frozen embryo (own eggs) testing market, 2014 - 2024 (USD Million)
6.5.2.4 Fresh embryo (donor eggs)
6.5.2.4.1 Global fresh embryo (donor eggs) testing market, 2014 - 2024 (USD Million)
6.5.2.5 Frozen embryo (donor eggs)
6.5.2.5.1 Global frozen embryo (donor eggs) testing market, 2014 - 2024 (USD Million)
6.5.3 Aneuploidy screening
6.5.3.1 Global aneuploidy screening market, 2014 - 2024 (USD Million)
6.5.4 HLA typing
6.5.4.1 Global HLA typing market, 2014 - 2024 (USD Million)
6.5.5 Other PGT (PGD/PGS) test types
6.5.5.1 Global other PGT (PGD/PGS) test types market, 2014 - 2024 (USD Million)

Chapter 7 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: Application Estimates & Trend Analysis
7.1 Definitions & Scope
7.2 Application Market Share Analysis, 2018 & 2024
7.3 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: End-use Movement Analysis, 2018 & 2024
7.4. Global Preimplantation Genetic Testing (PGT) (PGS/PGD) Market, by Application, 2014 to 2024
7.5 Market Size & Forecasts and Trend Analyses, 2014 to 2024 for the following,
7.5.1 Identifying embryo for stem cell therapy
7.5.1.1 Global identifying embryo for stem cell therapy market, 2014 - 2024 (USD Million)
7.5.2 IVF prognosis
7.5.2.1 Global IVF prognosis market, 2014 - 2024 (USD Million)
7.5.3 Late onset genetic disorders
7.5.3.1 Global late onset genetic disorders market, 2014 - 2024 (USD Million)
7.5.4 Inherited genetic disease
7.5.4.1 Global inherited genetic disease market, 2014 - 2024 (USD Million)
7.5.5 Others
7.5.5.1 Global other application market, 2014 - 2024 (USD Million)

Chapter 8 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market: Regional Estimates & Trend Analysis, by Product, Type & Application
8.1 Preimplantation Genetic Testing (PGT) (PGS/PGD) Market Share by Region, 2018 & 2024
8.2 Regional Market Share and Leading Players, 2018
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa
8.3 North America
8.3.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, 2014 - 2024 (USD Million)
8.3.2 U.S.
8.3.2.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.3.2.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.3.2.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.3.3 Canada
8.3.3.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.3.3.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.3.3.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4 Europe
8.4.1 Europe preimplantation genetic testing (PGT) (PGS/PGD) market, 2014 - 2024 (USD Million)
8.4.2 Germany
8.4.2.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.2.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.2.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.3 U.K.
8.4.3.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.3.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.3.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.4 Spain
8.4.4.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.4.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.4.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.5 Belgium
8.4.5.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.5.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.5.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.6 Czech Republic
8.4.6.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.6.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.6.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.7 Poland
8.4.7.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.7.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.7.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.8 Sweden
8.4.8.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.8.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.8.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.9 Finland
8.4.9.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.9.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.9.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.10 Norway
8.4.10.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.10.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.10.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.11 Netherlands
8.4.11.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.11.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.11.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.4.12 Italy
8.4.12.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.4.12.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.4.12.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.5 Asia Pacific
8.5.1 Asia Pacific preimplantation genetic testing (PGT) (PGS/PGD) market, 2014 - 2024 (USD Million)
8.5.2 Japan
8.5.2.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.5.2.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.5.2.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.5.3 China
8.5.3.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.5.3.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.5.3.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.5.4 India
8.5.4.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.5.4.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.5.4.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.5.5 Singapore
8.5.5.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.5.5.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.5.5.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.5.6 Malaysia
8.5.6.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.5.6.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.5.6.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.6 Latin America
8.6.1 Latin America preimplantation genetic testing (PGT) (PGS/PGD) market, 2014 - 2024 (USD Million)
8.6.2 Brazil
8.6.2.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.6.2.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.6.2.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.6.3 Mexico
8.6.3.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.6.3.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.6.3.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.6.4 Argentina
8.6.4.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.6.4.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.6.4.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.6.5 Chile
8.6.5.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.6.5.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.6.5.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)
8.7 Middle East & Africa
8.7.1 Middle East & Africa preimplantation genetic testing (PGT) (PGS/PGD) market, 2014 - 2024 (USD Million)
8.7.2 South Africa
8.7.2.1 Preimplantation genetic testing (PGT) (PGS/PGD) market, by PGD/PGS, 2014 - 2024 (USD Million)
8.7.2.2 Preimplantation genetic testing (PGT) (PGS/PGD) market, by type, 2014 - 2024 (USD Million)
8.7.2.3 Preimplantation genetic testing (PGT) (PGS/PGD) market, by application, 2014 - 2024 (USD Million)

Chapter 9 Pricing Analysis & Regulatory Framework Country-wise Customization
9.1 U.S.
9.1.1 Pricing analysis for PGD/PGS Tests
9.1.2 Regulatory framework for PGD/PGS Tests
9.2 Canada
9.2.1 Pricing analysis for PGD/PGS Tests
9.2.2 Regulatory framework for PGD/PGS Tests
9.3 Germany
9.3.1 Pricing analysis for PGD/PGS Tests
9.3.2 Regulatory framework for PGD/PGS Tests
9.4 U.K.
9.4.1 Pricing analysis for PGD/PGS Tests
9.4.2 Regulatory framework for PGD/PGS Tests
9.5 Spain
9.5.1 Pricing analysis for PGD/PGS Tests
9.5.2 Regulatory framework for PGD/PGS Tests
9.6 Belgium
9.6.1 Pricing analysis for PGD/PGS Tests
9.6.2 Regulatory framework for PGD/PGS services
9.7 Czech Republic
9.7.1 Pricing analysis for PGD/PGS Tests
9.7.2 Regulatory framework for PGD/PGS Tests
9.8 Poland
9.8.1 Pricing analysis for PGD/PGS Tests
9.8.2 Regulatory framework for PGD/PGS Tests
9.9 Sweden
9.9.1 Pricing analysis for PGD/PGS Tests
9.9.2 Regulatory framework for PGD/PGS Tests
9.10 Finland
9.10.1 Pricing analysis for PGD/PGS Tests
9.10.2 Regulatory framework for PGD/PGS Tests
9.11 Norway
9.11.1 Pricing analysis for PGD/PGS Tests
9.11.2 Regulatory framework for PGD/PGS services
9.12 Netherlands
9.12.1 Pricing analysis for PGD/PGS Tests
9.12.2 Regulatory framework for PGD/PGS Tests
9.13 Italy
9.13.1 Pricing analysis for PGD/PGS Tests
9.13.2 Regulatory framework for PGD/PGS Tests
9.14 Japan
9.14.1 Pricing analysis for PGD/PGS Tests
9.14.2 Regulatory framework for PGD/PGS Tests
9.15 China
9.15.1 Pricing analysis for PGD/PGS Tests
9.15.2 Regulatory framework for PGD/PGS Tests
9.16 India
9.16.1 Pricing analysis for PGD/PGS Tests
9.16.2 Regulatory framework for PGD/PGS Tests
9.17 Singapore
9.17.1 Pricing analysis for PGD/PGS Tests
9.17.2 Regulatory framework for PGD/PGS Tests
9.18 Malaysia
9.18.1 Pricing analysis for PGD/PGS Tests
9.18.2 Regulatory framework for PGD/PGS Tests
9.19 Brazil
9.19.1 Pricing analysis for PGD/PGS Tests
9.19.2 Regulatory framework for PGD/PGS Tests
9.20 Argentina
9.20.1 Pricing analysis for PGD/PGS Tests
9.20.2 Regulatory framework for PGD/PGS Tests
9.21 Chile
9.21.1 Pricing analysis for PGD/PGS Tests
9.21.2 Regulatory framework for PGD/PGS Tests
9.22 South Africa
9.22.1 Pricing analysis for PGD/PGS Tests
8.22.2 Regulatory framework for PGD/PGS Tests

Chapter 10 Competitive Landscape
10.1 Strategy framework
10.2 Market participation categorization
10.3 Company Profiles
10.3.1 F. Hoffmann-La Roche Ltd.
10.3.1.1 Company overview
10.3.1.1.1 Ariosa Diagnostics
10.3.1.2 Financial Performance
10.3.1.3 Product benchmarking
10.3.1.4 Strategic initiatives
10.3.2 Genea Limited
10.3.2.1 Company overview
10.3.2.2 Financial performance
10.3.2.3 Product benchmarking
10.3.2.4 Strategic initiatives
10.3.3 Quest Diagnostics Incorporated
10.3.3.1 Company overview
10.3.3.2 Financial performance
10.3.3.3 Product benchmarking
10.3.3.4 Strategic initiatives
10.3.4 Illumina, Inc.
10.3.4.1 Company overview
10.3.4.2 Financial performance
10.3.4.3 Product benchmarking
10.3.4.4 Strategic initiatives
10.3.5 Natera, Inc.
10.3.5.1 Company overview
10.3.5.2 Financial performance
10.3.5.3 Product benchmarking
10.3.5.4 Strategic initiatives
10.3.6 CooperSurgical, Inc.
10.3.6.1 Company overview
10.3.6.1.1 Genesis Genetics
10.3.6.1.2 Reprogenetics
10.3.6.2 Financial performance
10.3.6.2.1 Financial performance (Genesis Genetics)
10.3.6.2.2 Financial performance (Reprogenetics)
10.3.6.3 Product benchmarking
10.3.6.4 Strategic initiatives
10.3.7 Laboratory Corporation of America Holdings
10.3.7.1 Company overview
10.3.7.1.1 Sequenom
10.3.7.2 Financial performance
10.3.7.2.1 Financial performance (Sequenom)
10.3.7.3 Product benchmarking
10.3.7.4 Strategic initiatives
10.3.8 California Pacific Medical Center (CPMC)
10.3.8.1 Company overview
10.3.8.2 Financial performance
10.3.8.3 Product benchmarking
10.3.8.4 Strategic initiatives
10.3.9 Thermo Fisher Scientific, Inc.
10.3.9.1 Company overview
10.3.9.2 Financial performance
10.3.9.3 Product benchmarking
10.3.9.4 Strategic initiatives
10.3.10 IGENOMIX
10.3.10.1 Company overview
10.3.10.2 Financial performance
10.3.10.3 Product benchmarking
10.3.10.4 Strategic initiatives
10.3.11 Reproductive Genetic Innovations, LLC
10.3.11.1 Company overview
10.3.11.2 Financial performance
10.3.11.3 Product benchmarking
10.3.11.4 Strategic initiatives
10.3.12 Invitae Corporation
10.3.12.1 Company overview
10.3.12.1.1 CombiMatrix
10.3.12.1.2 Good Start Genetics, Inc.
10.3.12.2 Financial performance
10.3.12.3 Product benchmarking
10.3.12.4 Strategic initiatives
10.3.13 Oxford Gene Technology
10.3.13.1 Company overview
10.3.13.2 Financial performance
10.3.13.3 Product benchmarking
10.3.13.4 Strategic initiatives
10.3.14 Bioarray S.L.
10.3.14.1 Company overview
10.3.14.2 Financial performance
10.3.14.3 Product benchmarking
10.3.14.4 Strategic initiatives
10.3.15 PerkinElmer Inc.
10.3.15.1 Company overview
10.3.15.1.1 RHS Ltd.
10.3.15.2 Financial performance
10.3.15.3 Product benchmarking
10.3.15.4 Strategic initiatives
10.4 List of Companies

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • F. Hoffmann-La Roche Ltd.
  • Genea Limited
  • Quest Diagnostics Incorporated
  • Illumina, Inc.
  • Natera, Inc.
  • CooperSurgical, Inc.
  • Laboratory Corporation of America Holdings
  • California Pacific Medical Center (CPMC)
  • Thermo Fisher Scientific, Inc.
  • IGENOMIX
  • Reproductive Genetic Innovations, LLC
  • Invitae Corporation
  • Oxford Gene Technology
  • Bioarray S.L.
  • PerkinElmer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll